jnj-38877618
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT01964872)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
FC(F)(c1ccc2ncccc2c1)c1nnc2ccc(-c3ccncc3)nn12- Mol. weight
- 374.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095255 ↗
Also known as
- jnj-38877618
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01964872 | Phase 1 | Nov 1, 2013 | Janssen Pharmaceutica NV, Johnson and Johnson |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2013 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2013 |
2 organizations
Page 1 / 1